ADVANCED ONCOTHERAPY

Proving the accuracy and superiority of minibeams

The goal of Advanced Oncotherapy (AVO) is to deliver an affordable and more effective proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. In the past 18 months, the project has been de-risked through important technical milestones. AVO is now working on the verification and validation phase, prior to CE marking and LIGHT being used on the first patients. Meanwhile, AVO has entered into a research collaboration with the Cleveland Clinic aimed at proving the accuracy of targeting cancerous tissue, and sparing normal tissue, with proton minibeams in comparison with other methodologies.

- **Strategy**: AVO is developing a compact and modular PBT system, which is affordable for the payer, financially attractive to the operator, and generating superior patient outcomes. AVO benefits from technology know-how developed by ADAM (CERN spin-off) and relies on a world-class supplier base.

- **Collaboration**: The renowned Cleveland Clinic will undertake a two-year study to evaluate the target conformity of proton minibeams in comparison with stereotactic X-ray radiotherapy currently used for several types of cancer, particularly those located in the brain.

- **Goals**: Industry and oncologists are focused on overcoming the key challenge of ensuring that radiotherapy is targeted only at cancerous tissue, and avoiding healthy tissue. LIGHT has been designed for accuracy and improved patient outcomes. It is also being positioned to highlight its commercial advantages.

- **Risks**: Since 2018, the more complex technical challenges have been overcome, and progress towards a fully-functional accelerator is under way in readiness for CE marking. Execution risk remains, but management’s ability to raise funding and meet its milestones for the past 30 months has lowered this risk.

- **Investment summary**: AVO’s market capitalisation of £93m equates only to the amount invested into LIGHT to date, which does not reflect either the enormous technical challenges that have been overcome or the market potential. A DCF analysis of the LIGHT prospects generates an NPV of at least 224p per share (fully-diluted). The disconnect between fundamental and market valuations offers an interesting investment opportunity, in our opinion.

### Financial summary and valuation

<table>
<thead>
<tr>
<th>Year-end Dec (£m)</th>
<th>2017</th>
<th>2018</th>
<th>2019E</th>
<th>2020E</th>
<th>2021E</th>
<th>2022E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>21.5</td>
<td>65.5</td>
<td>111.5</td>
</tr>
<tr>
<td>Gross profit</td>
<td>0.0</td>
<td>-1.9</td>
<td>0.0</td>
<td>1.9</td>
<td>11.4</td>
<td>27.6</td>
</tr>
<tr>
<td>Administration costs</td>
<td>-12.9</td>
<td>-15.7</td>
<td>-15.0</td>
<td>-15.4</td>
<td>-15.8</td>
<td>-16.2</td>
</tr>
<tr>
<td>EBITDA</td>
<td>-14.1</td>
<td>-21.4</td>
<td>-18.9</td>
<td>-16.6</td>
<td>-10.5</td>
<td>1.6</td>
</tr>
<tr>
<td>Underlying EBIT</td>
<td>-14.5</td>
<td>-21.8</td>
<td>-20.6</td>
<td>-20.6</td>
<td>-14.6</td>
<td>-2.4</td>
</tr>
<tr>
<td>Statutory EBIT</td>
<td>-14.5</td>
<td>-21.8</td>
<td>-20.6</td>
<td>-21.2</td>
<td>-13.9</td>
<td>-0.7</td>
</tr>
<tr>
<td>Underlying PTP</td>
<td>-16.5</td>
<td>-21.9</td>
<td>-21.7</td>
<td>-22.3</td>
<td>-16.7</td>
<td>-4.6</td>
</tr>
<tr>
<td>Statutory PTP</td>
<td>-16.5</td>
<td>-21.9</td>
<td>-21.7</td>
<td>-22.9</td>
<td>-16.0</td>
<td>-2.9</td>
</tr>
<tr>
<td>Underlying EPS (p)</td>
<td>-17.6</td>
<td>-14.0</td>
<td>-8.9</td>
<td>-8.3</td>
<td>-6.1</td>
<td>-1.3</td>
</tr>
<tr>
<td>Statutory EPS (p)</td>
<td>-18.9</td>
<td>-13.4</td>
<td>-8.9</td>
<td>-8.5</td>
<td>-5.9</td>
<td>-0.7</td>
</tr>
<tr>
<td>Net (debt)/cash</td>
<td>-9.2</td>
<td>-2.0</td>
<td>-13.9</td>
<td>-21.5</td>
<td>-31.0</td>
<td>-34.7</td>
</tr>
<tr>
<td>EV/EBITDA (x)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

**Source**: Hardman & Co Life Sciences Research
Radiotherapy research collaboration

Two-year collaboration

AVO has signed a two-year research collaboration with the Cleveland Clinic, a leading academic medical centre, based in Cleveland, Ohio. This centre provides clinical and hospital care, and is a leader in research, education and health information. The aim of the collaboration is to evaluate the target conformality of proton minibeam radiation therapy in comparison with X-ray stereotactic radiosurgery (SRS).1

\[
\text{Target conformality (TC)} = \frac{\text{Volume of tissue receiving the prescription dose of radiation (PIV)}}{\text{Target volume (TV)}}
\]

As highlighted in our recent report, innovation in radiotherapy (RT) is focused on increasing the efficacy of treatment and improving quality of life for patients through a reduction of side effects or an increase in long-term survival rates. The most challenging goal for both the industry and the treating physicians is ensuring that RT is targeted only at cancerous tissue, and avoiding the irradiation of healthy tissue.

The use of a smaller proton beam (minibeams) means greater accuracy in targeting the desired tissue, which is essential when treating tumours that are near critical organs, particularly those close to the edge of the tumours. PBT is focused on initiatives to generate pencil-thin and more accurate beams. Indeed, AVO’s LIGHT system has been designed to generate an industry-leading minibeam (see below) compared with anything possible using current proton therapy technology.

Proton minibeam radiation therapy

A new approach in RT that allies the inherent physical advantages of protons with the normal tissue preservation observed when irradiated with sub-millimetric spatially fractionated beams (i.e. below the current standard size of proton beams) has been termed proton minibeam radiation therapy (pMBRT). A recent study described a dosimetry evaluation of pMBRT that was aimed at demonstrating the feasibility of the technical implementation of this technology. The study concluded that pMBRT was a novel strategy that could be used to reduce the side effects of RT. It provided the experimental proof-of-concept for pMBRT: clinical proton beams could be deposited in a (high) uniform dose in a brain tumour located in the centre of the brain (7.5 cm depth – the worst scenario), while a spatial fractionation of the dose could be retained in the normal tissues in the beam path, potentially leading to a gain in tissue sparing.

AVO’s LIGHT system is designed to provide pMBRT using the latest scanning technology. A figure of merit is shown comparing conventional PBT with pMBRT for a challenging tumour location in the base of the skull, encroaching on the brainstem (sensitive normal tissue). The colour wash in the figure on the left indicates the relative amount of radiation dose that the patient would receive from PBT and pMBRT. The pMBRT treatment plan is more sparing of the brainstem. The relative sparing

2 Conformality represents the ability of LIGHT to deliver a proton beam in such a way that the deposited radiation perfectly matches the irregular shapes of the tumour.
difference between PBT and pMBRT is observed in the lower tile of the figure, which highlights the advantages of using minibeams and sparing healthy tissues.

**X-ray stereotactic radiosurgery**

SRS is a non-surgical radiation therapy used to treat functional abnormalities and small tumours of the brain. It can deliver precisely-targeted radiation in fewer high-dose treatments than conventional therapy. When SRS is used to treat body tumours, it is called stereotactic body radiotherapy (SBRT).

As with most aims of the technologies/procedures described, the goal with SRS is to deliver a prescribed dose of radiation to the target geometry in as conformal a manner as possible, while spilling as little as possible into the surrounding normal tissue.

SRS uses many small, precisely-focused, radiation beams to treat tumours in the brain, neck, lungs, liver, spine and other parts of the body. Each beam has very little effect on the tissue it passes through, but a targeted dose of radiation is delivered to the site where all the beams intersect (see example graphic on left from Mayo Clinic). SRS is not surgery in the traditional sense, because no incisions are made; instead, it uses 3D imaging to target high doses of radiation to the affected area, with minimal impact on the surrounding healthy tissue.

Like other forms of radiation, SRS works by damaging the DNA of the targeted cells. The affected cells then lose the ability to reproduce, which causes tumours to shrink and blood vessels to close off over time following treatment, robbing the tumour of its blood supply. SRS of the brain and spine is typically completed in a single session, whereas body radiosurgery is used to treat lung, liver, adrenal and other soft tissue tumours, and treatment typically involves multiple sessions.

**A further scientific endorsement**

AVO has been able to form a very strong management team and attract key talent in the industry (the latest appointment being that of the previous head of Proton Therapy head of Varian as Chief Commercial Officer and President of North America). In addition, AVO has built a large network of suppliers with great track records. Today’s announcement is a further external endorsement that bodes well for the scientific reputation of the company. The following is a brief overview of the Cleveland Clinic:

- American academic medical centre based in Cleveland, Ohio.
- Owned and operated by the Cleveland Clinic, an Ohio non-profit corporation established in 1921.
- Runs a 170-acre campus in Cleveland, as well as 11 regional hospitals and 19 family health centres in northeast Ohio. Also manages hospitals in Florida and Nevada.
- Also operates outside of the US, with the Cleveland Clinic Abu Dhabi hospital, a sports medicine clinic in Toronto. In addition, it expects to have a hospital campus in London in 2021.
- Consistently ranked as one of the best hospitals in the US. In 2018-19, the U.S. News & World Report ranked the Cleveland Clinic as the number two hospital in the Best Hospitals Honor Roll, and it was nationally ranked in 14 adult and 10 paediatric specialties.
- It counted 7.6 million patient visits and 229,132 admissions in 2017.
- It has more than 60,000 employees, a figure that includes over 11,800 nurses, and over 3,953 physicians and scientists in 140 specialties.
- It is the first healthcare provider in the US to become a signatory to the United Nations Global Compact, and the second in the world.
Conclusion

Much of the research being undertaken in the field of PBT, together with clinical investigations, is aimed at focusing the RT onto the cancerous tissue while sparing normal tissue. The collaboration reported here and the previously reported use of ultra-efficient hypofractionation (FLASH technology) are both attempting to satisfy these goals.

The results of the collaboration with the Cleveland Clinic are not needed for the certification of LIGHT, but the quality and track record of the medical centre, together with the design of LIGHT that allows a much smaller proton beam to be generated, provide a further strong foundation of the superiority of LIGHT.

The LIGHT system being developed by AVO is particularly well positioned with respect to all these new initiatives and technologies:

► It generates high energy proton beams, but only up to the required level, avoiding the need for diffusers and associated high levels of shielding.
► It allows an ultra-fast (up to 200 times per second vs. 1-2 times per second for competitive systems) change of energy and deposition of radiation onto the tumour – hence optimising the effect of radiation on moving organs/tumours.
► It is suitable for hypofractionation procedures.
► It is suitable for FLASH technology.
► It is well positioned to reduce the number of hospital/clinic treatment visits to minimal levels and for the new US reimbursement model (assuming implementation in early 2020). It is well positioned for new US reimbursement model (assuming implementation in early 2020).

The collaboration with the Cleveland Clinic is designed to show that the accuracy of hypofractionated proton minibeams is at least as good as complex stereotactic radiotherapy with respect to target conformality.
Disclaimer

Hardman & Co provides professional independent research services and all information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable. However, no guarantee, warranty or representation, express or implied, can be given by Hardman & Co as to the accuracy, adequacy or completeness of the information contained in this research and they are not responsible for any errors or omissions or results obtained from use of such information. Neither Hardman & Co, nor any affiliates, officers, directors or employees accept any liability or responsibility in respect of the information which is subject to change without notice and may only be correct at the stated date of their issue, except in the case of gross negligence, fraud or wilful misconduct. In no event will Hardman & Co, its affiliates or any such parties be liable to you for any direct, special, indirect, consequential, incidental damages or any other damages of any kind even if Hardman & Co has been advised of the possibility thereof.

This research has been prepared purely for information purposes, and nothing in this report should be construed as an offer, or the solicitation of an offer, to buy or sell any security, product, service or investment. The research reflects the objective views of the analyst(s) named on the front page and does not constitute investment advice. However, the companies or legal entities covered in this research may pay us a fixed fee in order for this research to be made available. A full list of companies or legal entities that have paid us for coverage within the past 12 months can be viewed at http://www.hardmanandco.com/legals/research-disclosures. Hardman may provide other investment banking services to the companies or legal entities mentioned in this report.

Hardman & Co has a personal dealing policy which restricts staff and consultants’ dealing in shares, bonds or other related instruments of companies or legal entities which pay Hardman & Co for any services, including research. No Hardman & Co staff, consultants or officers are employed or engaged by the companies or legal entities covered by this document in any capacity other than through Hardman & Co.

Hardman & Co does not buy or sell shares, either for their own account or for other parties and neither do they undertake investment business. We may provide investment banking services to corporate clients. Hardman & Co does not make recommendations. Accordingly, they do not publish records of their past recommendations. Where a Fair Value price is given in a research note, such as a DCF or peer comparison, this is the theoretical result of a study of a range of possible outcomes, and not a forecast of a likely share price. Hardman & Co may publish further notes on these securities, companies and legal entities but has no scheduled commitment and may cease to follow these securities, companies and legal entities without notice.

The information provided in this document is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Hardman & Co or its affiliates to any registration requirement within such jurisdiction or country.

Some or all alternative investments may not be suitable for certain investors. Investments in small and mid-cap corporations and foreign entities are speculative and involve a high degree of risk. An investor could lose all or a substantial amount of his or her investment. Investments may be leveraged and performance may be volatile; they may have high fees and expenses that reduce returns. Securities or legal entities mentioned in this document may not be suitable or appropriate for all investors. Where this document refers to a particular tax treatment, the tax treatment will depend on each investor’s particular circumstances and may be subject to future change. Each investor’s particular needs, investment objectives and financial situation were not taken into account in the preparation of this document and the material contained herein. Each investor must make his or her own independent decisions and obtain their own independent advice regarding any information, projects, securities, tax treatment or financial instruments mentioned herein. The fact that Hardman & Co has made available through this document various information constitutes neither a recommendation to enter into a particular transaction nor a representation that any financial instrument is suitable or appropriate for you. Each investor should consider whether an investment strategy of the purchase or sale of any product or security is appropriate for them in the light of their investment needs, objectives and financial circumstances.

This document constitutes a ‘financial promotion’ for the purposes of section 21 Financial Services and Markets Act 2000 (United Kingdom) (FSMA) and accordingly has been approved by Capital Markets Strategy Ltd which is authorised and regulated by the Financial Conduct Authority (FCA).

No part of this document may be reproduced, stored in a retrieval system or transmitted in any form or by any means, mechanical, photocopying, recording or otherwise, without prior permission from Hardman & Co. By accepting this document, the recipient agrees to be bound by the limitations set out in this notice. This notice shall be governed and construed in accordance with English law. Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the FCA under registration number 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

(Disclaimer Version 8 – Effective from August 2018)